Skip to content
User

Parnassus Investments

Parnassus Endeavor Fund

Parnassus Endeavor Fund Novo Nordisk A/S stake

total: 118

Parnassus Endeavor Fund NVO trades

Total transactions:
6
New positions:
1
Sold out:
1
Added:
2
Reduced:
2
Held since:
2024 Q4
Held for:
5 quarters
Latest activity:
2026 Q1
According to 2026 Q2 report, Parnassus Endeavor Fund doesn't hold any Novo Nordisk A/S (NVO) shares. To date, the estimated cost basis is nearly $79.14 for "buy" trades and estimated average "sell" price is $50.89. Parnassus Endeavor Fund first purchased NVO in 2024 Q4, initially acquiring 593,722 shares. Since the initial investment in Novo Nordisk A/S (NVO), Parnassus Endeavor Fund has made 5 more transactions.

When did Parnassus Endeavor Fund sell Novo Nordisk A/S (NVO)?

Parnassus Endeavor Fund sold off the entire Novo Nordisk A/S (NVO) position in 2026 Q1.

When did Parnassus Endeavor Fund buy Novo Nordisk A/S (NVO)?

Parnassus Endeavor Fund first invested in Novo Nordisk A/S (NVO) in 2024 Q4 at the reported quarter-end price of $86.02 per share.

What's the cost basis of Parnassus Endeavor Fund's NVO stake?

The estimated cost basis for Novo Nordisk A/S (NVO) stake is around $79.14 per share. This represents their average reported price* across all buy transactions

Estimated cost basis*

Weighted AVG buy price:
$79.14
Weighted AVG sell price:
$50.89

Parnassus Endeavor Fund's historical trades in Novo Nordisk A/S

6 results
Period % of
portfolio
Shares
held after*
Reported
price*
Value* % (shares)
of activity
% change
to portfolio
2026 Q1
0.00%
0
$50.88
-100% (-964,103)
-1.03%
2025 Q4
1.03%
964,103
$50.88
$49,053,561
-4.46% (-45,017)
-0.05%
2025 Q3
1.19%
1,009,120
$55.49
$55,996,069
-0.24% (-2,426)
-0%
2025 Q2
1.54%
1,011,546
$69.02
$69,816,905
+9.23% (+85,463)
+0.13%
2025 Q1
1.44%
926,083
$69.44
$64,307,204
+55.98% (+332,361)
+0.52%
2024 Q4
1.06%
593,722
$86.02
$51,071,966
new
+1.06%
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.